Clinical Trials Logo

Cognitive Functioning clinical trials

View clinical trials related to Cognitive Functioning.

Filter by:
  • None
  • Page 1

NCT ID: NCT03497299 Not yet recruiting - Schizophrenia Clinical Trials

Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia

Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

Tobacco smokers with schizophrenia are known to be resistant smokers, with high rates of smoking and inability to quit in the long-term, often related to smoking relapse. This may relate to problems with frontal lobe function associated with schizophrenia, which make these patients have great difficulty in dealing with smoking withdrawal, urges and cravings. The current study will develop a combination approach that takes advantage of brain stimulation of the frontal lobes (repetitive transcranial magnetic stimulation (rTMS), in combination with the anti-smoking drug varenicline, to prevent smoking lapse using a well-established human laboratory method. Results from this study may have important implications for developing novel treatment approaches for smokers with schizophrenia.

NCT ID: NCT03328520 Completed - Depression Clinical Trials

WILD 5 Wellness, A 30-Day Intervention

Start date: October 24, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to explore the efficacy and feasibility of an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition in First Year Beloit College students self-selected into a wellness focused first year initiative. This program is called "WILD 5 Wellness: A 30-Day Intervention".

NCT ID: NCT02739139 Completed - Clinical trials for Cognitive Functioning

Efficacy Study of AlphaBRAIN Administered Orally

Start date: February 2013
Phase: Phase 2
Study type: Interventional

The manufacturers of AlphaBRAIN(TM) claim that their product, when taken as directed, has beneficial effects on cognition. The active ingredient in AlphaBRAIN, Huperzine A, is a naturally occurring compound found in firmoss and also thought to be an acetylcholinesterase inhibitor. Numerous clinical studies have been undertaken to investigate the effects of Huperzine A on cognition and have demonstrated benefit to cognition in both individuals diagnosed with neurodegenerative diseases as well as performance on academic tasks by students. However, to our knowledge, there are no randomized controlled trials evaluating the effects of AlphaBRAIN(TM) on cognition. Thus, the purpose of the current study is to assess the effects of daily oral administration of AlphaBRAIN(TM) on cognitive functioning, as compared to placebo, after 45 days of treatment. 1. To evaluate a single daily dose of AlphaBRAIN(TM) vs placebo given orally on the change in a battery of standardized neuropsychological tests (see attached). 2. A secondary objective is to evaluate a single daily dose of AlphaBRAIN(TM) vs placebo given orally on sleep.

NCT ID: NCT01720472 Active, not recruiting - Aging Clinical Trials

Implementing a Physical and Cognitive Performance Assessment Cohort in the MURDOCK Study Community Registry and Biorepository

PPS
Start date: May 2012
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to use the MURDOCK Horizon 1.5 infrastructure (Duke Instutional Review Board Pro00011196) to specifically target and enroll 1,000 participants across age groups and other demographic categories in order to develop a diverse cohort with specific physical and cognitive performance data paired with biological samples.